Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

Launched by CIUSSS DE L'EST DE L'ÎLE DE MONTRÉAL · Apr 25, 2024

Keywords

ClinConnect Summary

This clinical trial, called OLIP-EBV-TCL-01-HMR01, is focused on treating a specific type of cancer known as EBV-associated lymphoma in a young adult patient who has already undergone a stem cell transplant. The goal of the trial is to help strengthen the patient’s immune system by using special cells called EBV-specific T cells, which are designed to help the body fight off the cancer caused by the Epstein-Barr virus (EBV).

To participate in this trial, the patient must be at least 18 years old, able to understand and agree to the treatment, and must not be pregnant. They also need to be using effective contraception if they could become pregnant. It’s important to note that patients who have recently received certain treatments or have specific health conditions may not be eligible. Participants in this study can expect close monitoring and support as they receive this experimental treatment, which aims to improve their chances of recovery from this serious condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Capacity to provide informed consent
• • 2. Age ≥ 18
• • 3. Negative serum pregnancy test and use of effective contraception method.
• Exclusion Criteria:
• • 1. Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath)
• • 2. Pregnancy
• • 3. Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome.
• • 4. Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.